Volume 85 Issue 3 | p. 33 | Concentrates
Issue Date: January 15, 2007

BioVectra scores production contract

Department: Business

BioVectra, a Canadian custom pharmaceutical manufacturer, has won the contract to supply Helix BioPharma with bulk quantities of L-DOS47, consisting of a single-domain antibody linked to the enzyme urease. BioVectra will make clinical-trial quantities of the drug, for which Helix is currently completing preclinical tests as a lung cancer treatment. According to Helix, BioVectra was selected because it has biopharmaceutical production capabilities and is a major supplier of urease.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment